Research graph
References from An evaluation of mitapivat for the treatment of non-transfusion-dependent alpha- and beta-thalassemia. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1002/ajh.27621
10.1002/ajh.27621 · External reference
10.3324/haematol.2012.066845
10.3324/haematol.2012.066845 · External reference
10.1016/j.blre.2023.101165
10.1016/j.blre.2023.101165 · External reference
10.1016/j.bcmd.2006.04.005
10.1016/j.bcmd.2006.04.005 · External reference
10.1016/s0140-6736(79)92175-5
10.1016/s0140-6736(79)92175-5 · External reference
10.1111/j.1365-2141.2010.08220.x
10.1111/j.1365-2141.2010.08220.x · External reference
10.1002/ajh.27194
10.1002/ajh.27194 · External reference
10.1016/s0140-6736(25)00635-x
10.1016/s0140-6736(25)00635-x · External reference
Unresolved reference
External reference
10.1016/s0268-960x(12)70003-6
10.1016/s0268-960x(12)70003-6 · External reference
10.1182/blood-2010-01-251348
10.1182/blood-2010-01-251348 · External reference
10.3109/07853890.2015.1091942
10.3109/07853890.2015.1091942 · External reference
10.1182/bloodadvances.2026020059
10.1182/bloodadvances.2026020059 · External reference
10.1182/blood-2011-12-397729
10.1182/blood-2011-12-397729 · External reference
10.1182/blood-2018-07-815928
10.1182/blood-2018-07-815928 · External reference
10.1182/hematology.2023000468
10.1182/hematology.2023000468 · External reference
10.3389/fphys.2021.754638
10.3389/fphys.2021.754638 · External reference
10.1182/blood-2019-129996
10.1182/blood-2019-129996 · External reference
10.1111/j.1365-2141.1994.tb05072.x
10.1111/j.1365-2141.1994.tb05072.x · External reference
10.1016/j.arcmed.2012.02.003
10.1016/j.arcmed.2012.02.003 · External reference
10.1007/s00277-019-03659-1
10.1007/s00277-019-03659-1 · External reference
10.1182/blood.v99.1.36
10.1182/blood.v99.1.36 · External reference
10.1016/s0268-960x(12)70007-3
10.1016/s0268-960x(12)70007-3 · External reference
10.1111/jdv.12211
10.1111/jdv.12211 · External reference
Unresolved reference
2023 · External reference
10.1016/j.dld.2010.07.006
10.1016/j.dld.2010.07.006 · External reference
10.1016/j.bcmd.2012.06.001
10.1016/j.bcmd.2012.06.001 · External reference
10.4084/mjhid.2019.026
10.4084/mjhid.2019.026 · External reference
10.23750/abm.v88i4.6837
10.23750/abm.v88i4.6837 · External reference
10.1007/s00277-020-04370-2
10.1007/s00277-020-04370-2 · External reference
10.1002/ajh.26428
10.1002/ajh.26428 · External reference
10.1007/s00277-021-04456-5
10.1007/s00277-021-04456-5 · External reference
10.1016/j.jtumed.2023.05.002
10.1016/j.jtumed.2023.05.002 · External reference
10.18502/ijph.v51i1.8287
10.18502/ijph.v51i1.8287 · External reference
10.1016/j.ejim.2011.05.013
10.1016/j.ejim.2011.05.013 · External reference
10.1182/blood-2009-04-210112
10.1182/blood-2009-04-210112 · External reference
10.1111/j.1600-0609.2010.01509.x
10.1111/j.1600-0609.2010.01509.x · External reference
10.1136/hrt.2005.079970
10.1136/hrt.2005.079970 · External reference
10.1007/bf02983382
10.1007/bf02983382 · External reference
10.1007/s00277-004-1002-4
10.1007/s00277-004-1002-4 · External reference
10.1002/ajh.20640
10.1002/ajh.20640 · External reference
10.1111/j.1365-2141.2000.02376.x
10.1111/j.1365-2141.2000.02376.x · External reference
10.1111/j.1538-7836.2010.03940.x
10.1111/j.1538-7836.2010.03940.x · External reference
Long-term hemoglobin improvements in non-transfusion-dependent alpha- or beta-thalassemia: results from the open-label extension of the ongoing phase 3 energize trial
2026 · External reference
10.1016/s2352-3026(22)00208-3
10.1016/s2352-3026(22)00208-3 · External reference
10.1182/bloodadvances.2025016554
10.1182/bloodadvances.2025016554 · External reference
10.1002/14651858.cd013767.pub2
10.1002/14651858.cd013767.pub2 · External reference
10.1182/blood-2012-10-408021
10.1182/blood-2012-10-408021 · External reference
10.1016/j.hemonc.2017.02.002
10.1016/j.hemonc.2017.02.002 · External reference
10.3109/08880010903271671
10.3109/08880010903271671 · External reference
10.1016/j.chembiol.2012.07.021
10.1016/j.chembiol.2012.07.021 · External reference
10.1177/20406207211066070
10.1177/20406207211066070 · External reference
10.1080/17474086.2022.2125865
10.1080/17474086.2022.2125865 · External reference
10.3324/haematol.2019.240846
10.3324/haematol.2019.240846 · External reference
10.1002/ajh.25926
10.1002/ajh.25926 · External reference
10.1111/ejh.13572
10.1111/ejh.13572 · External reference
10.1080/16078454.2023.2290746
10.1080/16078454.2023.2290746 · External reference
10.1056/nejmoa1902678
10.1056/nejmoa1902678 · External reference
10.1016/s2352-3026(23)00377-0
10.1016/s2352-3026(23)00377-0 · External reference
10.1056/nejmoa2116634
10.1056/nejmoa2116634 · External reference
10.1016/s2352-3026(22)00214-9
10.1016/s2352-3026(22)00214-9 · External reference
10.1172/jci144206
10.1172/jci144206 · External reference
10.1182/blood.2020008635
10.1182/blood.2020008635 · External reference
10.1172/jci.insight.172656
10.1172/jci.insight.172656 · External reference
10.1002/ajh.27442
10.1002/ajh.27442 · External reference
10.1002/pbc.31440
10.1002/pbc.31440 · External reference
10.21037/atm-2026-1-0021
10.21037/atm-2026-1-0021 · External reference
10.1182/bloodadvances.2021004675
10.1182/bloodadvances.2021004675 · External reference
10.1002/ajh.27312
10.1002/ajh.27312 · External reference
10.1002/ajh.26830
10.1002/ajh.26830 · External reference
10.1182/bloodadvances.2023011743
10.1182/bloodadvances.2023011743 · External reference
10.3324/haematol.2023.282884
10.3324/haematol.2023.282884 · External reference
Unresolved reference
External reference
10.1182/blood-2016-11-753525
10.1182/blood-2016-11-753525 · External reference
10.3324/haematol.2019.238865
10.3324/haematol.2019.238865 · External reference
Preclinical pharmacokinetic/pharmacodynamic relationships for AG-348, an investigational small-molecule activator of pyruvate kinase
2015 · External reference
10.1002/cpdd.604
10.1002/cpdd.604 · External reference
10.1111/cts.13609
10.1111/cts.13609 · External reference
10.1016/s0140-6736(22)01337-x
10.1016/s0140-6736(22)01337-x · External reference
10.1111/bjh.20058
10.1111/bjh.20058 · External reference
10.1111/j.1537-2995.2007.01416.x
10.1111/j.1537-2995.2007.01416.x · External reference
10.1080/03630269.2022.2072320
10.1080/03630269.2022.2072320 · External reference
10.1001/jamanetworkopen.2021.44386
10.1001/jamanetworkopen.2021.44386 · External reference
10.1182/blood.v96.7.2606
10.1182/blood.v96.7.2606 · External reference
Effects of mitapivat on iron burden and spleen size in erythrocyte membranopathies and congenital dyserythropoietic anemia type ii: 56-week follow-up results from the satisfy study
2026 · External reference
RoxyScan assesses pyruvate kinase activator’s effect on oxidative stress sensitivity in ß-thalassemia patients: an ancillary study of the ENERGIZE/ENERGIZE-T clinical trials
2025 · External reference
10.1056/nejmra2212266
10.1056/nejmra2212266 · External reference
Etavopivat improves hemoglobin levels in adults and adolescents with non-transfusion-dependent alpha- or beta-thalassemia: results from the open-label phase 2 gladiolus study
2026 · External reference
